HoldsUp

Eric Topol

Eric Topol is a medical researcher whose work focuses heavily on the application and evaluation of artificial intelligence and digital technologies across healthcare. His published research explores clinical AI foundation models, dynamic AI evaluation, robotic surgery, and biological aging clocks. Additionally, he has published studies on multi-cancer early detection, COVID-19 treatments, metabolic mechanisms in neurodegeneration, and appraisals of the wellness industry.

14 claims checked on air: 3 overstated 11 supported

What they said on air

0:26:26supportedhighIt's Not Cholesterol. Inflammation Is What's Actually Causin

Heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all heart failure cases.

"preserve ejection fraction heart failure, which is half of all heart failure, right?" (said at 0:26:26)

Large population-based epidemiological studies establish that heart failure with preserved ejection fraction (HFpEF) accounts for approximately 50% (roughly 45% to 55%) of all heart failure cases in clinical practice and community cohorts.

0:26:30supportedmoderateIt's Not Cholesterol. Inflammation Is What's Actually Causin

GLP-1 receptor agonist drugs reduce systemic inflammation independently of and prior to weight loss.

"We've already seen how GLP-1 drugs do that before any weight loss. So that should work well in people who aren't even obese." (said at 0:26:30)

Randomized clinical trials and translational research demonstrate that GLP-1 receptor agonists exert direct anti-inflammatory effects that occur acutely (even following a single dose) and independently of weight reduction. In human trials, GLP-1 receptor agonism rapidly downregulates reactive oxygen species generation, NF-κB binding, and proinflammatory cytokine expression (including TNF-α, IL-1β, and IL-6) as well as systemic markers such as high-sensitivity C-reactive protein before or in the absence of significant weight loss.

0:26:40supportedhighIt's Not Cholesterol. Inflammation Is What's Actually Causin

GLP-1 receptor agonist medications prevent or improve heart failure with preserved ejection fraction (HFpEF).

"And we've seen how that can prevent heart—preserve ejection fraction heart failure, which is half of all heart failure, right? GLP-1s prevent that." (said at 0:26:40)

Large phase 3 randomized controlled trials have demonstrated that the GLP-1 receptor agonist semaglutide substantially improves symptoms, physical functioning, and clinical outcomes in patients with heart failure with preserved ejection fraction (HFpEF). In the STEP-HFpEF and STEP-HFpEF DM trials, once-weekly semaglutide significantly improved Kansas City Cardiomyopathy Questionnaire (KCCQ-CSS) scores and 6-minute walk distance while reducing body weight compared with placebo in patients with obesity-related HFpEF. Furthermore, a pooled analysis of 3,743 participants across four randomized trials (STEP-HFpEF, STEP-HFpEF DM, SELECT, and FLOW) showed that semaglutide significantly reduced the risk of worsening heart failure events (HR 0.59, 95% CI 0.41–0.82) and composite cardiovascular death or heart failure events (HR 0.69, 95% CI 0.53–0.89).

0:27:20overstatedmoderateIt's Not Cholesterol. Inflammation Is What's Actually Causin

Artificial intelligence analysis of retinal photographs can predict the onset of Alzheimer's disease 5 to 7 years in advance.

"You can do a retina AI exam. So I have a picture of the retina and you do AI on it, and it tells you when you're going to have Alzheimer's, if you're going to have Alzheimer's 5 to 7 years in advance." (said at 0:27:20)

Large prospective cohort studies (including data from the UK Biobank) demonstrate that artificial intelligence and deep-learning models applied to retinal photographs or optical coherence tomography can identify retinal structural features and biological aging markers associated with an increased relative risk of developing Alzheimer's disease or dementia years (e.g., 5 to 12 years) before clinical diagnosis. However, framing this as a ready clinical exam that deterministically "tells you when you're going to have Alzheimer's, if you're going to have Alzheimer's" significantly overstates the evidence. Current AI retinal models quantify statistical risk and biological vulnerability in research cohorts; they are not clinically diagnostic or deterministic prognostic tests for individual patients.

0:27:40supportedmoderateIt's Not Cholesterol. Inflammation Is What's Actually Causin

AI analysis of retinal images can predict coronary artery calcium scores, stroke risk, and heart disease.

"The retina also tells if you're going to have heart disease or a stroke in advance. It will even tell if you're going to, um, you know, your calcium score of your heart arteries through your retina." (said at 0:27:40)

Published studies confirm that artificial intelligence and deep-learning models applied to retinal fundus photographs can predict coronary artery calcium (CAC) scores, incident cardiovascular disease, and stroke risk. Deep-learning algorithms have demonstrated discrimination of high CAC scores (>100) from zero CAC with an AUROC of approximately 0.83. Furthermore, systematic reviews and cohort studies show that retinal microvascular biomarkers and AI retinal models predict future cardiovascular events (such as myocardial infarction, cardiovascular mortality, and stroke) with predictive accuracy comparable to conventional clinical risk scores.

0:28:49supportedmoderateIt's Not Cholesterol. Inflammation Is What's Actually Causin

Pericoronary arterial inflammation detected by AI analysis on CT angiography in the absence of arterial narrowing is associated with up to a 15-fold increased risk of heart attack.

"No, no, the Cleerly and the other ones in the US don't do this, but this is a a a Oxford, University of Oxford spinout. I think it's called Caristo. They're going to have that available soon. And I went through the data in the book. I mean, they've had multiple papers, but it's striking. If you have inflammation without a narrow, it's, you know, you could have 15-fold risk of a heart attack." (said at 0:28:49)

The claim is supported by large prospective cohort data from University of Oxford researchers and the associated spinout technology (Caristo's AI-assisted perivascular Fat Attenuation Index [FAI] Score). In the ORFAN multicentre longitudinal cohort study published in The Lancet (2024), coronary inflammation measured by FAI Score on coronary CT angiography was evaluated in patients with and without obstructive coronary artery disease. Having high perivascular inflammation across coronary arteries was associated with a 12.6-fold increased risk of major adverse cardiac events (MACE, including myocardial infarction; HR 12.6, 95% CI 8.5–18.6) and a nearly 30-fold increased risk of cardiac mortality, independent of anatomical stenosis.

0:29:50supportedmoderateIt's Not Cholesterol. Inflammation Is What's Actually Causin

Adhering to comprehensive healthy lifestyle practices provides 7 to 10 additional years of life free from major age-related chronic diseases.

"show that if we practice the lifestyle factors that we've been reviewing with the details, um, that we we discussed, that gets us 7 to 10 years of healthy aging without one of these age-related diseases." (said at 0:29:50)

A prospective analysis of 111,562 participants from the Nurses' Health Study and the Health Professionals Follow-Up Study investigated the impact of five low-risk lifestyle factors (a healthy diet, never smoking, ≥30 minutes/day of moderate-to-vigorous physical activity, moderate alcohol consumption, and a normal BMI). At age 50, women adhering to four or five healthy lifestyle factors had 34.4 years of life expectancy free of diabetes, cardiovascular disease, and cancer compared to 23.7 years for those with zero factors (a gain of 10.7 disease-free years). For men, the disease-free life expectancy at age 50 was 31.1 years versus 23.5 years (a gain of 7.6 disease-free years), directly supporting the claim of 7 to 10 additional years of life free from major chronic diseases.

0:31:12supportedhighIt's Not Cholesterol. Inflammation Is What's Actually Causin

Clinical trial data demonstrate that the lower LDL cholesterol is reduced, the greater the cardiovascular protection.

"Well, if you look at all the data, the lower you go, the more protection" (said at 0:31:12)

Large meta-analyses of randomized controlled trials (such as the Cholesterol Treatment Trialists' Collaboration) and individual trial analyses (such as FOURIER and FOURIER-OLE) demonstrate a consistent, log-linear relationship where lower achieved low-density lipoprotein cholesterol (LDL-C) levels yield progressively greater reductions in major cardiovascular events, without a discernible lower threshold for clinical efficacy down to very low LDL-C levels (<20 mg/dL).

0:32:24overstatedhighIt's Not Cholesterol. Inflammation Is What's Actually Causin

Statins cause severe leg cramps and muscle-related symptoms in patients.

"Some of the data that comes out of these big meta-analyses, which say, "Oh, people don't get any leg cramps." That's not true. You and I know that's not true. People do get severe leg cramps where they can't even sleep at night, you know, uh, and and all sorts of other, you know, leg, uh, and muscle-related symptoms." (said at 0:32:24)

While statin therapy is causally associated with a small excess rate of muscle pain or weakness, the severity and frequency attributed to statins are significantly overstated. A comprehensive individual participant data meta-analysis of 19 large double-blind, placebo-controlled randomized trials (n=123,940) by the Cholesterol Treatment Trialists' Collaboration found that statins caused a small excess of mostly mild muscle symptoms during the first year of treatment (absolute excess of 11 events per 1,000 person-years; rate ratio 1.07). However, after the first year, there was no significant excess risk, and more than 90% of all muscle symptom reports among statin-treated participants were not attributable to the drug, occurring at near-identical rates in the placebo groups (nocebo/drucebo effect and background prevalence). Severe muscle damage (such as rhabdomyolysis or severe myopathy) is very rare.

0:32:45supportedhighIt's Not Cholesterol. Inflammation Is What's Actually Causin

Clinical data do not show that statins cause cognitive impairment or sexual dysfunction.

"Now, with respect to cognitive and, uh, sexual dysfunction, the data really don't show a hit there at all" (said at 0:32:45)

High-certainty evidence from randomized controlled trials and meta-analyses supports the claim that clinical data do not demonstrate a causal link between statin therapy and cognitive impairment or sexual dysfunction. A meta-analysis of individual participant data from 19 double-blind randomized trials encompassing 123,940 individuals found no evidence that statins cause cognitive impairment or other non-hepatic/non-muscular undesirable effects listed in product labels. Furthermore, systematic reviews and meta-analyses of randomized controlled trials evaluating lipid-lowering therapies (including statins) have found no significant association with neurocognitive disorders or global cognitive decline compared to placebo or control groups.

0:32:54supportedhighIt's Not Cholesterol. Inflammation Is What's Actually Causin

Alzheimer's disease accounts for 70% of dementia cases.

"and Alzheimer's, as you know, accounts for 70% of dementia" (said at 0:32:54)

Epidemiological consensus establishes that Alzheimer's disease is the leading cause of dementia, accounting for an estimated 60% to 70% of all dementia cases globally.

0:33:00overstatedmoderateIt's Not Cholesterol. Inflammation Is What's Actually Causin

Failing to lower LDL cholesterol below 100 mg/dL or 70 mg/dL places individuals at higher risk for dementia.

"if you don't have the LDL lowered to let's say less than 100, less than 70, you're going to be at higher risk for dementia." (said at 0:33:00)

While some observational cohort analyses find that individuals with LDL cholesterol levels below 70 mg/dL have lower rates of incident dementia compared to those with higher levels, randomized controlled trial evidence does not support the claim that actively lowering LDL cholesterol to specific targets (e.g., <100 or <70 mg/dL) reduces dementia risk. Cochrane systematic reviews of randomized trials evaluating statin-induced LDL lowering found no significant reduction in the incidence of dementia or Alzheimer's disease, and trial data from PCSK9 inhibitor studies similarly show no significant effect on dementia outcomes.

0:34:00supportedhighIt's Not Cholesterol. Inflammation Is What's Actually Causin

High doses of potent statins like rosuvastatin and atorvastatin increase the risk of developing type 2 diabetes.

"because if you take a very potent statin, you have a higher risk of developing type 2 diabetes, right? ... high doses of rosuvastatin, Crestor, or atorvastatin, Lipitor, that could also raise the risk of that person developing type 2 diabetes." (said at 0:34:00)

Large meta-analyses of randomized controlled trials demonstrate that statin therapy—and particularly intensive-dose or high-potency statin regimens such as high-dose atorvastatin and rosuvastatin—is associated with a modest, statistically significant increase in the risk of developing new-onset type 2 diabetes. A 2011 meta-analysis of 5 randomized trials (32,752 participants) comparing intensive-dose to moderate-dose statin therapy found a 12% increased odds of incident diabetes (OR 1.12, 95% CI 1.04–1.22), representing roughly 2.0 additional cases of diabetes per 1,000 patient-years. This dose-dependent diabetogenic effect is well recognized, although guidelines emphasize that cardiovascular benefits generally outweigh this risk in indicated patients.

0:35:53supportedhighIt's Not Cholesterol. Inflammation Is What's Actually Causin

PCSK9 inhibitor injectable medications are not associated with an increased risk of diabetes.

"the PCSK9 injectable drugs are a winner because they're potent and they have not been associated with diabetes" (said at 0:35:53)

Extensive randomized controlled trial evidence and systematic reviews demonstrate that injectable PCSK9 monoclonal antibodies (such as evolocumab and alirocumab) do not increase the risk of new-onset diabetes or impair glycemic parameters (fasting plasma glucose, HbA1c), unlike statin therapy. A 2022 systematic review and meta-analysis of 32 trials comprising 65,861 participants evaluated this outcome with high certainty evidence and confirmed no increased risk of new-onset diabetes.

Fact-checked episodes

Publications